Can we improve patient selection for phase I clinical trials (phI1) based on immuno-oncology score prognostic index (VIO)?
Abstract
Background null Life expectancy longer than 12 weeks(w) is a common inclusion criteria for most Ph1. Despite the presence of several prognostic indeces in drug development, their value for patient selection in clinical trials is not well established. VIO is a immune-oncology score validated in patients treated in Ph1 with immunotherapy (Hierro C. ESMO 2018), which includes 5 variables: albumin null upper limit normal, dNLR (derived...
Paper Details
Title
Can we improve patient selection for phase I clinical trials (phI1) based on immuno-oncology score prognostic index (VIO)?
Published Date
Oct 1, 2019
Journal
Volume
30
Pages
v42 - v42
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History